MXPA06005031A - Combinacion de un inhibidor de la farnesil transferasa con un agente antihormonal para el tratamiento de cancer mamario. - Google Patents
Combinacion de un inhibidor de la farnesil transferasa con un agente antihormonal para el tratamiento de cancer mamario.Info
- Publication number
- MXPA06005031A MXPA06005031A MXPA06005031A MXPA06005031A MXPA06005031A MX PA06005031 A MXPA06005031 A MX PA06005031A MX PA06005031 A MXPA06005031 A MX PA06005031A MX PA06005031 A MXPA06005031 A MX PA06005031A MX PA06005031 A MXPA06005031 A MX PA06005031A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- fti
- breast cancer
- tamoxifen
- administration
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 389
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 175
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 142
- 239000013059 antihormonal agent Substances 0.000 title claims abstract description 35
- 239000003112 inhibitor Substances 0.000 title claims description 9
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 title 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims abstract description 71
- 229960002932 anastrozole Drugs 0.000 claims abstract description 70
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 70
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 70
- 239000000328 estrogen antagonist Substances 0.000 claims abstract description 47
- 229940046836 anti-estrogen Drugs 0.000 claims abstract description 46
- 230000001833 anti-estrogenic effect Effects 0.000 claims abstract description 46
- 239000003886 aromatase inhibitor Substances 0.000 claims abstract description 32
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940122815 Aromatase inhibitor Drugs 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 183
- 229960001603 tamoxifen Drugs 0.000 claims description 91
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 54
- 229960003881 letrozole Drugs 0.000 claims description 53
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 39
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 39
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 39
- 229960000397 bevacizumab Drugs 0.000 claims description 38
- 229960001467 bortezomib Drugs 0.000 claims description 38
- 229960005395 cetuximab Drugs 0.000 claims description 38
- 229960002584 gefitinib Drugs 0.000 claims description 38
- 102000014654 Aromatase Human genes 0.000 claims description 35
- 108010078554 Aromatase Proteins 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 35
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 34
- 229960000255 exemestane Drugs 0.000 claims description 33
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 29
- 229960004622 raloxifene Drugs 0.000 claims description 28
- -1 Fulvestran Chemical compound 0.000 claims description 25
- 108010069236 Goserelin Proteins 0.000 claims description 24
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 24
- 229960004421 formestane Drugs 0.000 claims description 24
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 24
- 229960002913 goserelin Drugs 0.000 claims description 23
- 108010000817 Leuprolide Proteins 0.000 claims description 20
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 19
- 229950011548 fadrozole Drugs 0.000 claims description 19
- 229960004338 leuprorelin Drugs 0.000 claims description 19
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 18
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 239000002434 gonadorelin derivative Substances 0.000 claims description 5
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 119
- 229960000575 trastuzumab Drugs 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 abstract description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 abstract description 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 abstract description 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 abstract description 2
- 230000005855 radiation Effects 0.000 abstract description 2
- 229960002258 fulvestrant Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 description 101
- 210000004027 cell Anatomy 0.000 description 54
- 206010028980 Neoplasm Diseases 0.000 description 40
- 230000012010 growth Effects 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000004614 tumor growth Effects 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 4
- 229960005471 androstenedione Drugs 0.000 description 4
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 3
- 238000009115 maintenance therapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 229950008696 farnesil Drugs 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000183290 Scleropages leichardti Species 0.000 description 1
- 241001116459 Sequoia Species 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51782003P | 2003-11-06 | 2003-11-06 | |
| PCT/US2004/036859 WO2005046691A1 (en) | 2003-11-06 | 2004-11-04 | Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06005031A true MXPA06005031A (es) | 2006-07-06 |
Family
ID=34590193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06005031A MXPA06005031A (es) | 2003-11-06 | 2004-11-04 | Combinacion de un inhibidor de la farnesil transferasa con un agente antihormonal para el tratamiento de cancer mamario. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050119188A1 (https=) |
| EP (1) | EP1680118A1 (https=) |
| JP (1) | JP2007510661A (https=) |
| CN (1) | CN1917877A (https=) |
| AU (1) | AU2004289256A1 (https=) |
| BR (1) | BRPI0416316A (https=) |
| CA (1) | CA2544421A1 (https=) |
| MX (1) | MXPA06005031A (https=) |
| NO (1) | NO20062582L (https=) |
| TW (1) | TW200526215A (https=) |
| WO (1) | WO2005046691A1 (https=) |
| ZA (1) | ZA200603597B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060024691A1 (en) * | 2004-03-25 | 2006-02-02 | Buck Institute For Age Research | Novel pathways in the etiology of cancer |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| WO2009145852A1 (en) * | 2008-04-17 | 2009-12-03 | Concert Pharmaceuticals, Inc. | Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof |
| EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
| SI1255537T1 (sl) * | 2000-02-04 | 2006-10-31 | Janssen Pharmaceutica Nv | Inhibitorji farnezil protein transferaze za zdravljenje raka dojk |
| US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| CA2424797C (en) * | 2000-10-05 | 2009-12-29 | George Q. Daley | Methods of inducing cancer cell death and tumor regression |
| DE60230017D1 (de) * | 2001-02-15 | 2009-01-08 | Janssen Pharmaceutica Nv | Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen |
| WO2003047697A2 (en) * | 2001-11-30 | 2003-06-12 | Schering Corporation | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| AU2002346644A1 (en) * | 2001-12-03 | 2003-06-17 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
-
2004
- 2004-11-04 JP JP2006538492A patent/JP2007510661A/ja active Pending
- 2004-11-04 US US10/980,915 patent/US20050119188A1/en not_active Abandoned
- 2004-11-04 AU AU2004289256A patent/AU2004289256A1/en not_active Abandoned
- 2004-11-04 WO PCT/US2004/036859 patent/WO2005046691A1/en not_active Ceased
- 2004-11-04 CN CNA2004800323958A patent/CN1917877A/zh active Pending
- 2004-11-04 MX MXPA06005031A patent/MXPA06005031A/es unknown
- 2004-11-04 TW TW093133659A patent/TW200526215A/zh unknown
- 2004-11-04 EP EP04810378A patent/EP1680118A1/en not_active Withdrawn
- 2004-11-04 BR BRPI0416316-8A patent/BRPI0416316A/pt not_active IP Right Cessation
- 2004-11-04 CA CA002544421A patent/CA2544421A1/en not_active Abandoned
-
2006
- 2006-05-05 ZA ZA200603597A patent/ZA200603597B/en unknown
- 2006-06-02 NO NO20062582A patent/NO20062582L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1680118A1 (en) | 2006-07-19 |
| JP2007510661A (ja) | 2007-04-26 |
| WO2005046691A1 (en) | 2005-05-26 |
| CA2544421A1 (en) | 2005-05-26 |
| BRPI0416316A (pt) | 2007-01-09 |
| CN1917877A (zh) | 2007-02-21 |
| NO20062582L (no) | 2006-08-02 |
| ZA200603597B (en) | 2007-07-25 |
| TW200526215A (en) | 2005-08-16 |
| US20050119188A1 (en) | 2005-06-02 |
| AU2004289256A1 (en) | 2005-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stan et al. | Breast cancer survivorship issues | |
| Morotti et al. | Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study | |
| Peivandi et al. | Effect of letrozole on spermogram parameters and hormonal profile in infertile men: A clinical trial study | |
| Lee et al. | Effects of hormone therapy on serum lipid levels in postmenopausal Korean women | |
| Josefson et al. | Growth hormone excess in children with optic pathway tumors is a transient phenomenon | |
| AU2016208673B2 (en) | Antihistamine for use in treatment of breast cancer | |
| CN110755431B (zh) | 地氯雷他定在制备抗肝癌药物中的应用 | |
| US20250319084A1 (en) | Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer | |
| Tejuja | Use of subcutaneous silastic capsules for long-term steroid contraception | |
| MXPA06005031A (es) | Combinacion de un inhibidor de la farnesil transferasa con un agente antihormonal para el tratamiento de cancer mamario. | |
| JP7361779B2 (ja) | がんに治療的処置をするためのｃ－１９ステロイドの組み合わせ | |
| US20240316064A1 (en) | Use of estretol as a treatment for endometriosis | |
| US11285143B2 (en) | Use of mTOR inhibitor and chloroquine for treating cancer | |
| US20170035783A1 (en) | Composition for the prevention and therapy of tumor diseases | |
| UA51627C2 (uk) | Відновлення тонічної секреції естрогену з яєчників для довгочасних схем лікування | |
| EP3127544A1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| US20250367252A1 (en) | Goserelin implant dosing regimens for improved patient compliance | |
| Palmieri et al. | Recent advances in adjuvant therapy for breast cancer | |
| Bashir et al. | Current Available Pharmacological Interventions for PCOS: Oral Contraceptive Pills | |
| Brownley et al. | Successful pregnancy after bilateral adrenalectomy for Cushing's syndrome | |
| CN118660706A (zh) | Cdk4和6抑制剂与氟维司群组合用于在cdk4和6抑制剂先前治疗的患者中治疗激素受体阳性、人表皮生长因子受体2阴性晚期或转移性乳腺癌 | |
| EISFELDER | Clinical Evaluation of Estrone, Estradiol Benzoate and Diethylstilbestrol | |
| Ansfield | Chemotherapy of breast cancer | |
| CN103340847A (zh) | 二甲磺酸乙烷的医药用途 | |
| JPH05500947A (ja) | 薬剤製造のための抗ゲスターゲンの使用 |